Special items: Ovarian Cancer and Us blog best viewed in Firefox

Sunday, March 07, 2010

repost: Combination therapy: intermittent Sorafenib with (Avastin) bevacizumab yields activity and decreased toxicity.


No comments:

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.